Kaitlyn H. Ko
Research Subjects
Kaitlyn H. Ko has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Merve Sahin
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NYC, NY, USA
2 shared publications - Rebecca Gelfer
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
2 shared publications - Sheng F. Cai
Human Oncology and Pathogenesis Program, Center for Hematologic Malignancies and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
2 shared publications - Wenbin Xiao
Memorial Sloan Kettering Cancer Center
2 shared publications Adeela Kamal
1 shared publication- Angelica C. Romero-Vega
Memorial Sloan Kettering Cancer Center 4 New York, New York
1 shared publication
Latest Publications
- Open Access
- 10 November 2026
- Published by Elsevier in Blood Neoplasia
Actimab-A, a CD33-targeted Actinium-225 radioconjugate, drives potent mutation-agnostic efficacy in AML models
- 10 November 2026
- Published by Elsevier in Blood Neoplasia
Open AccessActimab-A, a CD33-targeted Actinium-225 radioconjugate, drives potent mutation-agnostic efficacy in AML models
- 30 September 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
Very Long Chain Fatty Acid Synthesis is a Targetable Dependency in RAS Pathway Mutant Leukemia
Oncogenic RAS pathway mutations are associated with therapeutic resistance in acute myeloid leukemia, and identification of therapeutic vulnerabilities has been hindered by a lack of clinically relevant models and tractable ex vivo platforms. We utilize a bone marrow endothelial cell co-culture system to perform CRISPR screens on wild-type hematopoietic cells and isogenic leukemias with and without mutant Nras. We credentialed Elovl1, a very long chain fatty acid elongase, as a dependency in RAS pathway mutant leukemia using genetic and pharmacologic approaches. Metabolic and genetic studies in primary leukemias revealed that the fitness defect from Elovl1 loss reflects a mutant-specific dependency on de novo sphingolipid biosynthesis, specifically sphingomyelin production, as Sgms1 deletion phenocopies Elovl1 loss. Sphingomyelin-mediated generation of lipid rafts, key scaffolds for multiple signaling pathways, is essential to the survival of Nras-mutant AML cells. Our work leverages a new leukemia model to identify a targetable dependency in this treatment-refractory leukemia.
- 30 September 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
Very Long Chain Fatty Acid Synthesis is a Targetable Dependency in RAS Pathway Mutant Leukemia
Oncogenic RAS pathway mutations are associated with therapeutic resistance in acute myeloid leukemia, and identification of therapeutic vulnerabilities has been hindered by a lack of clinically relevant models and tractable ex vivo platforms. We utilize a bone marrow endothelial cell co-culture system to perform CRISPR screens on wild-type hematopoietic cells and isogenic leukemias with and without mutant Nras. We credentialed Elovl1, a very long chain fatty acid elongase, as a dependency in RAS pathway mutant leukemia using genetic and pharmacologic approaches. Metabolic and genetic studies in primary leukemias revealed that the fitness defect from Elovl1 loss reflects a mutant-specific dependency on de novo sphingolipid biosynthesis, specifically sphingomyelin production, as Sgms1 deletion phenocopies Elovl1 loss. Sphingomyelin-mediated generation of lipid rafts, key scaffolds for multiple signaling pathways, is essential to the survival of Nras-mutant AML cells. Our work leverages a new leukemia model to identify a targetable dependency in this treatment-refractory leukemia.
- Open Access
- 20 March 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (3) , 169
Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions
Acute myeloid leukemia (AML) is a molecularly heterogeneous neoplasm of hematopoietic stem and progenitor cells. The advent of high-resolution genomic sequencing has uncovered several genetic drivers of AML which spurred a surge of therapies that target the disease at a mutational, clonal, or epigenetic level. Currently, the molecular profiling of AML patients before treatment is commonplace and crucial for ensuring that patients receive the most optimal therapy for any driver mutations they may have. Here, we detail the current targeted therapies available for AML: specifically, those targeting the BCL2 family (venetoclax), FLT3 (midostaurin, gilteritinib, quizartinib), IDH1/2 (enasidenib, ivosidenib), and MENIN (revumenib, ziftomenib). In addition, we outline potential mechanisms of resistance against these therapies, as well as efforts being taken to prevent or bypass them.
- 20 March 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (3) , 169
Open AccessTargeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions
Acute myeloid leukemia (AML) is a molecularly heterogeneous neoplasm of hematopoietic stem and progenitor cells. The advent of high-resolution genomic sequencing has uncovered several genetic drivers of AML which spurred a surge of therapies that target the disease at a mutational, clonal, or epigenetic level. Currently, the molecular profiling of AML patients before treatment is commonplace and crucial for ensuring that patients receive the most optimal therapy for any driver mutations they may have. Here, we detail the current targeted therapies available for AML: specifically, those targeting the BCL2 family (venetoclax), FLT3 (midostaurin, gilteritinib, quizartinib), IDH1/2 (enasidenib, ivosidenib), and MENIN (revumenib, ziftomenib). In addition, we outline potential mechanisms of resistance against these therapies, as well as efforts being taken to prevent or bypass them.